Liver transplant surgery and transfusion

International Anesthesiology Clinics

Volumn 42, Issue 3, 2004, Pages 147-162

  Ozier, Yves ^a   Albi, Aline ^a  

^a université Paris Cité   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTITHROMBIN; APROTININ; LYSINE DERIVATIVE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; SERINE PROTEINASE INHIBITOR; TRANEXAMIC ACID;

BLEEDING; BLEEDING DISORDER; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; DRUG HYPERSENSITIVITY; FIBRINOLYSIS; HUMAN; INTRAOPERATIVE PERIOD; LIVER TRANSPLANTATION; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; SURGICAL RISK; THROMBOSIS;

ANTIFIBRINOLYTIC AGENTS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; BLOOD VOLUME; HUMANS; INTRAOPERATIVE CARE; LIVER TRANSPLANTATION;

EID: 3242666968     PISSN: 00205907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004311-200404230-00012     Document Type: Review

References (74)

1. Palomo Sanchez JC, Jimenez C, Moreno Gonzalez E, et al. Effects of intraoperative blood transfusion on postoperatíve complications and survival after orthotopic liver transplantation. Hepatogastroenterology. 1998;45:1026-1033.
2. Cacciarelli TV, Keeffe EB, Moore DH, et al. Effect of intraoperative blood transfusion on patient outcome in hepatic transplantation. Arch Surg. 1999;134:25-29.
3. Bontempo FA, Lewis JH, VanThiel D, et al. The relation of preoperative coagulation finding to diagnosis, blood usage, and survival in adult liver transplantation. Transplantation. 1985;39:532-536.
4. Lichtor JL, Emond J, Chung MR, et al. Pediatric orthotopic liver transplantation: multifactorial predictions of blood loss. Anesthesiology. 1988;68:607-611.
5. Carlier M, Van Obbergh L, Veyckemans F, et al. Hemostasis in children undergoing liver transplantation. Semin Thromb Hemost. 1993;19:218-222.
6. Deakin M, Gunson BK, Dunn JA, et al. Factors influencing blood transfusion during adult liver transplantation. Ann R Coll Surg Engl. 1993;75:339-344.
7. Mor E, Jennings L, Gonwa TA, et al. The impact of operative bleeding on outcome in transplantation of the liver. Surg Gynecol Obst. 1993;176:219-227.
8. Ozier Y, Le Cam B, Chatellier C, et al. Intraoperative blood loss in pediatric liver transplantation: analysis of preoperative risk factors. Anesth Analg. 1995;81:1142-1147.
9. Findlay JY, Rettke SR. Poor prediction of blood transfusion requirements in adult liver transplantations from preoperative variables. J Clin Anesth. 2000;12:319-323.
10. Steib A, Freys G, Lehmann C, et al. Intraoperative blood losses and transfusion requirements during adult liver transplantation remain difficult to predict. Can J Anaesth. 2001;48:1075-1079.
11. Cuervas-Mons V, Rimola A, Van Thiel DH, et al. Does previous abdominal surgery alter the outcome of pediatric patients subjected to orthotopic liver transplantation? Gastroenterology. 1986;90:853-857.
12. Mammen EF. Coagulation defects in liver disease. Med Clin North Am. 1994;78:545-554.
13. Pereira SP, Langley PG, Williams R. The management of abnormalities of hemostasis in acute liver failure. Semin Liver Dis. 1996;16:403-414.
14. Ben-Ari Z, Osman E, Hutton RA, et al. Disseminated intravascular coagulation in liver cirrhosis: fact or fiction? Am J Gastroenterol. 1999;94:2977-2982.
15. Leebeek FWG, Kluft C, Knot EAR, et al. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. Gastroenterology. 1991;101:1382-1390.
16. Segal H, Cottam S, Potter D, et al. Coagulation and fibrinolysis in primary biliary cirrhosis compared with other liver disease and during orthotopic liver transplantation. Hepatolog. 1997;25:683-688.
17. Ben-Ari Z, Panagou M, Patch D, et al. Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thromboelastography. J Hepatol, 1997;26:554-559.
18. Steib A, Gengenwin N, Freys G, et al. Predictive factors of hyperfibrinolytic activity during liver transplantation in cirrhotic patients. BrJAnaesth. 1994;73:645-648.
19. Ritter DM, Rettke SR, Lunn RJ, et al. Preoperative coagulation screen does not predict intraoperative blood product requirements in orthotopic liver transplantation. Transplant Proc. 1989;21:3533-3534.
20. Gerlach H, Slama KJ, Bechstein WO, et al. Retrospective statistical analysis of coagulation parameters after 250 liver transplantations. Semin Thromb Hemost. 1993;19:223-232.
21. Kang YG, Lewis JH, Navalgund A, et al. Epsilon-aminocaproic acid for treatment of fibrinolysis during liver transplantation. Anesthesiology. 1987;66:766-773.
22. Shaw BW, Martin DJ, Marquez JM, et al. Venous bypass in clinical liver transplantation. Ann Surg. 1984;200:524-534.
23. Jones R, Hardy KJ, Fletcher DR, et al. Preservation of the inferior vena cava in orthotopic liver transplantation with selective use of veno-venous bypass: the piggy back operation. Transplant Proc. 1992;24:189-191.
24. Kang YG, Martin DJ, Marquez JM, et al. Intraoperative changes in blood coagulation and thromboelastographic monitoring in liver transplantation. Anesth Analg. 1985;64:888-896.
25. Dzik WH, Arkin CF, Jenkins RL, et al. Fibrinolysis during liver transplantation in humans: role of tissue-type plasminogen activator. Blood. 1988;71:1090-1095.
26. Arnoux D, Boutière B, Houvenaeghel M, et al. Intraoperative evolution of coagulation parameters and t-PA/PAI balance in orthotopic liver transplantation. Thromb Res. 1989;55:319-328.
27. Grosse H, Lobbes W, Sato M, et al. Systemic fibrigenolysis in liver transplantation. Transplant Proc. 1990;22:2302-2304.
28. Porte RJ, Bontempo FA, Knot EA, et al. Systemic effects of tissue plasminogen activator-associated fibrinolysis and its relation to thrombin generation in orthotopic liver transplantation. Transplantation. 1989;47:978-984.
29. Bakker CM, Metselaar HJ, Groenland TN, et al. Increased tissue-type plasminogen activator in orthotopic but not heterotopic liver transplantation: the role of the anhepatic period. Hepatology. 1992;16:404-408.
30. Harper PL, Luddington RL, Jennings I, et al. Coagulation changes following hepatic revascularization during liver transplantation. Transplantation. 1989;48:603-607.
31. Porte RJ, Knot EAR, Bontempo FA. Hemostasis in liver transplantation. Gastroenterology. 1989;97:488-501.
32. Himmelreich G, Hundt K, Neuhaus P, et al. Decreased platelet aggregation after reperfusion in orthotopic liver transplantation. Transplantation. 1992;53:582-586.
33. Weber T, Marino IR, Kang YG, et al. Intraoperative blood transfusions in highly alloimmunized patients undergoing orthotopic liver transplantation. Transplantation. 1989;47:797-801.
34. Bakker CM, Stibbe J, Groenland TN, et al. The appearance of donor heparin in the recipient after reperfusion of a liver graft. Transplantation. 1993;56:327-329.
35. Bayly PJM, Thick M. Reversal of post-reperfusion coagulopathy by protamine sulphate in orthotopic liver transplantation. Br J Anaesth. 1994;73:840-842.
36. Kettner SC, Gonano C, Seebach F, et al. Endogenous heparin-like substances significantly impair coagulation in patients undergoing orthotopic liver transplantation. Anesth Analg. 1998;86:691-695.
37. Harding SA, Mallett SV, Peachey TD, et al. Use of heparinase modified thromboelastography in liver transplantation. Br J Anaesth. 1997;78:175-179.
38. Boylan JF, Klinck JR, Sandler AN, et al. Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation. Anesthesiology. 1996;85:1043-1048.
39. Kaspar M, Ramsay MAE, Nguyen AT, et al. Continuous small-dose tranexamic acid reduces fibrinolysis but not transfusion requirements during orthotopic liver transplantation. Anesth Analg. 1997;85:281-285.
40. Dalmau A, Sabate A, Acosta F, et al. Tranexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation. Anesth Analg. 2000;91:29-34.
41. Neuhaus P, Bechstein WO, Lefebre B, et al. Effect of aprotinin on intraoperative bleeding and fibrinolysis in liver transplantation. Lancet. 1989;2:924-925.
42. Mallet SV, Cox D, Burroughs AL, et al. Aprotinin and reduction of blood loss in orthotopic liver transplantation. Lancet. 1990;2:886-887.
43. Grosse H, Lobbes W, Frambach M, et al. The use of high-dose aprotinin in liver transplantation: the influence on fibrinolysis and blood loss. Thromb Res. 1991;63:287-297.
44. Garcia-Huete L, Domenech P, Sabate A, et al. The prophylactic effect of aprotinin on intraoperative bleeding in liver transplantation: a randomized clinical study. Hepatology. 1997;26:1143-1148.
45. Marcel RJ, Stegall WC, Suit CT, et al. Continuous small-dose aprotinin controls fibrinolysis during orthotopic liver transplantation. Anesth Analg. 1996;82:1122-1125.
46. Porte RJ, Molenaar IQ Begliomini B, et al. Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. EMSALT Study Group. Lancet. 2000;355:1303-1309.
47. Laupacis A, Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of Peri-operative Transfusion (ISPOT) Investigators. Anesth Analg. 1997;85:1258-1267.
48. Dietrich W, Spath P, Zuhlsdorf M, et al. Anaphylactic reactions to aprotinin reexposure in cardiac surgery: relation to antiaprotinin immunoglobulin G and E antibodies. Anesthesiology. 2001;95:64-71; discussion 5A-6A.
49. Molenaar IQ Begliomini B, Grazi GL, et al. The effect of aprotinin on renal function in orthotopic liver transplantation. Transplantation. 2001;71:247-252.
50. Molenaar IQ Legnani C, Groenland TH, et al. Aprotinin in orthotopic liver transplantation: evidence for a prohemostatic, but not a prothrombotic, effect. Liver Transpl 2001;7:896-903.
51. Dalmau A, Sabate A, Koo M, et al. Prophylactic use of tranexamic acid and incidence of arterial thrombosis in liver transplantation. Anesth Analg. 2001;93:516.
52. Baubillier E, Cherqui D, Dominique C, et al. A fatal thrombotic complication during liver transplantation after aprotinin administration. Transplantation. 1994;57:1664-1666.
53. Sopher M, Braunfeld M, Shakleton C, et al. Fatal pulmonary embolism during liver transplantation. Anesthesiology. 1997;87:429-432.
54. O'Connor CJ, Roozeboom D, Brown R, et al. Pulmonary thromboembolism during liver transplantation: possible association with antifibrinolytic drugs and novel treatment options. Anesth Analg. 2000;91:296-299.
55. Bernstein DE, Jeffers L, Erhardtsen E, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology. 1997;113:1930-1937.
56. Lisman T, Leebeek FW, Meijer K, et al. Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation. Hepatology. 2002;35:616-621.
57. Ejlersen E, Melsen T, Ingerslev J, et al. Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices. Scand J Gastroenterol. 2001;36:1081-1085.
58. Hendriks HG, Meijer K, De Wolf JT, et al. Effects of recombinant activated factor VII on coagulation measured by thromboelastography in liver transplantation. Blood Coagul Fibrinolysis. 2002;13:309-313.
59. Baudo F, DeGasperi A, deCataldo F, et al. Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. Thromb Res. 1992;68:409-416.
60. Klinck JR. Liver transplantation: Anesthesia. In: Klinck JR, Lindop MJ, editors. Anesthesia and Intensive Care for Organ Transplantation. London: Chapman & Hall; 1998:169-199.
61. Dupont J, Messiant F, Declerck N, et al. Liver transplantation without the use of fresh frozen plasma. Anesth Analg. 1996;83:681-686.
62. Kang YG, Gasior TA. Blood coagulation during liver, kidney, pancreas, and lung transplantation. In: Spiess BD, Counts RB, Gould SA, editors. Perioperative Transfusion Medicine. Baltimore, MD: Williams & Wilkins; 1998:471-492.
63. Azad SC, Kratzer MA, Groh J, et al. Intraoperative monitoring and postoperative reevaluation of hemostasis in orthotopic liver transplantation. Semin Thromb Hemost. 1993;19:233-237.
64. Ickx B, Pradier O, DeGroote F, et al. Effect of two different dosages of aprotinin on perioperative blood loss during liver transplantation. Semin Thromb Hemost. 1993;19:300-301.
65. Kang Y. Transfusion based on clinical coagulation monitoring does reduce hemorrhage during liver transplantation. Liver Transpl Surg. 1997;3:655-659.
66. Reyle-Hahn M, Rossaint R. Coagulation techniques are not important in directing blood product transfusion during liver transplantation. Liver Transpl Surg. 1997;3:659-663.
67. Murray D, Pennell B, Olson J. Variability of prothrombin time and activated partial thromboplastin time in the diagnosis of increased surgical bleeding. Transfusion. 1999;39:56-62; discussion 63-65.
68. McNicol PL, Liu G, Harley ID, et al. Patterns of coagulopathy during liver transplantation: experience with the first 75 cases using thromboelastography. Anaesth Intensive Care. 1994;22:659-665.
69. Palareti G, Legnani C, Maccaferri M, et al. Coagulation and fibrinolysis in orthotopic liver transplantation: role of the recipient's disease and use of antithrombin III concentrates. S. Orsola Working Group on Liver Transplantation. Haemostasis. 1991;21:68-76.
70. Gerlach H, Rossaint R, Bechstein WO, et al. Goal-directed transfusion management leads to distinct reduction of fluid requirement in liver transplantation. Semin Thromb Hemost. 1993;19:282-285.
71. Hadengue A, Moreau R, Gaudin C, et al. Total effective vascular compliance in patients with cirrhosis: a study of the response to acute blood volume expansion. Hepatology. 1992;15:809-815.
72. Williamson LM, Llewelyn CA, Fisher NC, et al. A randomized trial of solvent/detergenttreated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion. 1999;39:1227-1234.
73. Coignard B, Nguyen GT, Tokars J, et al. A cluster of intra-operative deaths in a liver transplant center associated with the use of solvent/detergent plasma. Presented at: Proceedings of the 11th Annual Meeting of the Society for Healthcare Epidemiology of America; 2001.
74. de Jonge J, Groenland TH, Metselaar HJ, et al. Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP). Anesth Analg. 2002;94:1127-1131.